Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Long-acting antimalarials could provide improved prophylaxis and treatment options in the field. Here, Bakshi et al. develop a long-acting injectable atovaquone nanomedicine that prevents malaria infection prophylactically for up to 4 weeks in mice with no evidence for generation of resistant parasi...
Guardado en:
Autores principales: | Rahul P. Bakshi, Lee M. Tatham, Alison C. Savage, Abhai K. Tripathi, Godfree Mlambo, Matthew M. Ippolito, Elizabeth Nenortas, Steve P. Rannard, Andrew Owen, Theresa A. Shapiro |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e2bbca833b9043c393d3ffbbdc23b805 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immune Regulation of <italic toggle="yes">Plasmodium</italic> Is <italic toggle="yes">Anopheles</italic> Species Specific and Infection Intensity Dependent
por: Maria L. Simões, et al.
Publicado: (2017) -
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
por: Thomas M. Ashton, et al.
Publicado: (2016) -
Gametocytocidal screen identifies novel chemical classes with Plasmodium falciparum transmission blocking activity.
por: Natalie G Sanders, et al.
Publicado: (2014) -
CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies
por: Hanagata N
Publicado: (2017) -
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies
por: Marco Giardiello, et al.
Publicado: (2016)